The period for CME/CE credit for this activity has expired.


This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .


CME Post-Test - Incretin Insider: Incretin Mimetics 2008 in Review


INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

1. Compared with intravenous glucose, oral ingestion of glucose is associated with _______ insulin secretion.
A: An increase in
B: A decrease in
C: Comparable
D: Negligible

2. The two key incretin hormones that have been shown to affect glucoregulation are:
A: GLP-1 and GLP-2
B: GIP-1 and GIP-2
C: GLP-1 and GIP
D: GIP and GLP-2

3. Which of the following is NOT true of native GLP-1?
A: It promotes insulin secretion in a glucose-dependent manner
B: It suppresses glucagon secretion, independent of glucose levels
C: It promotes β-cell mass in animal models
D: It promotes satiety and weight loss

4. Exenatide, a synthetic version of exendin-4 administered twice daily, has a ____% amino acid sequence homology with native GLP-1.
A: 33
B: 53
C: 73
D: 93

5. A meta-analysis showed that twice daily exenatide reduced A1C by approximately ____%.
A: 0.5
B: 0.7
C: 1.0
D: 1.5

6. A comparison of twice-daily exenatide and sitagliptin showed that reduction in postprandial glucose levels were:
A: Greater with sitagliptin than with exenatide
B: Greater with exenatide than with sitagliptin
C: Comparable with exenatide and sitagliptin
D: Negligible with both exenatide and sitagliptin

7. The incretin mimetic liraglutide has a ____% amino acid sequence homology with native GLP-1.
A: 37
B: 57
C: 77
D: 97

8. Results of the LEAD studies have demonstrated that 1.8 mg liraglutide once daily reduces A1C by approximately:
A: 0.5%-0.70%
B: 0.7%-0.9%
C: 0.9%-1.0%
D: 1.0%-1.5%

9. Which of the following statements is NOT true with respect to the LEAD 6 study?
A: Liraglutide was associated with a significantly greater decrease from baseline A1C compared with exenatide
B: Liraglutide was associated with a significantly greater decrease in FPG compared with exenatide
C: Exenatide was associated with a significantly greater reduction in weight compared with liraglutide
D: The rates of nausea were similar between groups

10. Compared with exenatide, exenatide LAR:
A: Has a longer half-life
B: Is associated with greater improvements in glycemic control
C: Is associated with a lower incidence of nausea
D: All of the above

Return to Activity